342 related articles for article (PubMed ID: 28411455)
1. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
Zhao F; Zhang LD; Hao Y; Chen N; Bai R; Wang YJ; Zhang CC; Li GS; Hao LJ; Shi C; Zhang J; Mao Y; Fan Y; Xia GX; Yu JX; Liu YJ
Eur J Med Chem; 2017 Jul; 134():147-158. PubMed ID: 28411455
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
[TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
[TBL] [Abstract][Full Text] [Related]
4. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.
Jia H; Dai G; Weng J; Zhang Z; Wang Q; Zhou F; Jiao L; Cui Y; Ren Y; Fan S; Zhou J; Qing W; Gu Y; Wang J; Sai Y; Su W
J Med Chem; 2014 Sep; 57(18):7577-89. PubMed ID: 25148209
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor.
Zhan Z; Peng X; Liu Q; Chen F; Ji Y; Yao S; Xi Y; Lin Y; Chen T; Xu Y; Ai J; Geng M; Duan W
Eur J Med Chem; 2016 Jun; 116():239-251. PubMed ID: 27061987
[TBL] [Abstract][Full Text] [Related]
6. Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.
Cui JJ; Shen H; Tran-Dubé M; Nambu M; McTigue M; Grodsky N; Ryan K; Yamazaki S; Aguirre S; Parker M; Li Q; Zou H; Christensen J
J Med Chem; 2013 Sep; 56(17):6651-65. PubMed ID: 23944843
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.
Peterson EA; Teffera Y; Albrecht BK; Bauer D; Bellon SF; Boezio A; Boezio C; Broome MA; Choquette D; Copeland KW; Dussault I; Lewis R; Lin MH; Lohman J; Liu J; Potashman M; Rex K; Shimanovich R; Whittington DA; Vaida KR; Harmange JC
J Med Chem; 2015 Mar; 58(5):2417-30. PubMed ID: 25699405
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
9. Discovery andw biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors.
Zhou S; Liao H; Liu M; Feng G; Fu B; Li R; Cheng M; Zhao Y; Gong P
Bioorg Med Chem; 2014 Nov; 22(22):6438-52. PubMed ID: 25438768
[TBL] [Abstract][Full Text] [Related]
10. [Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Szokol B; Gyulavári P; Baska F; Ibolya K; Greff Z; Szántai KC; Zoltán O; Peták I; Axel U; Vantus T; Kéri G; Orfi L
Acta Pharm Hung; 2013; 83(4):121-33. PubMed ID: 24575658
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.
Liu M; Hou Y; Yin W; Zhou S; Qian P; Guo Z; Xu L; Zhao Y
Eur J Med Chem; 2016 Aug; 119():96-108. PubMed ID: 27155466
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate.
Chen T; Zhuo LS; Liu PF; Fang WR; Li YM; Huang W
Eur J Med Chem; 2020 Apr; 192():112174. PubMed ID: 32113049
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives as selective c-Met inhibitors.
Wang X; Jiang N; Zhao S; Xi S; Wang J; Jing T; Zhang W; Guo M; Gong P; Zhai X
Bioorg Med Chem; 2017 Feb; 25(3):886-896. PubMed ID: 28011202
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
Li S; Zhao Y; Wang K; Gao Y; Han J; Cui B; Gong P
Bioorg Med Chem; 2013 Jun; 21(11):2843-55. PubMed ID: 23628470
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of c-Met Kinase Inhibitors Containing Quinoline by Aldehyde Oxidase, Electron Donating, and Steric Hindrance Effect.
Zhang JW; Xiao W; Gao ZT; Yu ZT; Zhang JYJ
Drug Metab Dispos; 2018 Dec; 46(12):1847-1855. PubMed ID: 30209037
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2.
Xu H; Wang M; Wu F; Zhuo L; Huang W; She N
Bioorg Med Chem; 2020 Jun; 28(12):115555. PubMed ID: 32503697
[TBL] [Abstract][Full Text] [Related]
18. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
Nan X; Li HJ; Fang SB; Li QY; Wu YC
Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
[TBL] [Abstract][Full Text] [Related]
19. Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.
Morgillo F; Amendola G; Della Corte CM; Giacomelli C; Botta L; Di Maro S; Messere A; Ciaramella V; Taliani S; Marinelli L; Trincavelli ML; Martini C; Novellino E; Ciardiello F; Cosconati S
J Med Chem; 2017 Sep; 60(17):7447-7458. PubMed ID: 28787156
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
